NDA 204326 · Neos Theraps
Adzenys Xr-Odt
Amphetamine · Oral · Central Nervous System Stimulant
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jan 27, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
392
60 Phase 3, 36 recruiting
FAERS reports
6,299
5,284 serious, 3,007 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE AND ADDICTION Amphetamine extended-release orally disintegrating tablets has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including amphetamine extended-release orally disintegrating tablets, can result in overdose and death [ see Overdosage ( 10 )], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing amphetamine extended-release orally disintegrating tablets, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout amphetamine extended-release orally disintegrating tablets treatment, reassess each patient’s risk of abuse, misuse, and...
What it is approved for
From the label in effect Oct 1, 2026.
Amphetamine extended-release orally disintegrating tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies ( 14 )]. Limitations of Use The use of amphetamine extended-release orally disintegrating tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g. weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5). Use in Specific Populations (8.4) ]. Amphetamine extended-release orally disintegrating tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. ( 1 ) Limitations of Use The use of amphetamine extended-release orally disintegrating tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage. (5.5, 8.4)
Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
6 products under this application
- ADZENYS XR-ODT · AMPHETAMINE EQ 18.8MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
- ADZENYS XR-ODT · AMPHETAMINE EQ 12.5MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
- ADZENYS XR-ODT · AMPHETAMINE EQ 6.3MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
- ADZENYS XR-ODT · AMPHETAMINE EQ 15.7MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
- ADZENYS XR-ODT · AMPHETAMINE EQ 9.4MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
- ADZENYS XR-ODT · AMPHETAMINE EQ 3.1MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amphetamine" as an intervention, any sponsor and status, largest first.
- A Toolbox Approach to Obesity Treatment in Primary CarePivotal-lookingCompleted
Denver Health and Hospital AuthorityAcademic, hospital or other
NCT01922934 · 4,730 participants · Start Jan 2014 · Primary completion Aug 2016
Drug: Obesity pharmacotherapy · For: Obesity
Sites: Denver, Colorado
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01435759 · 1,197 participants · Start May 31, 2011 · Primary completion Jan 17, 2014
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg and 3 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Chino, California · 82 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436162 · 1,105 participants · Start Oct 19, 2011 · Primary completion Dec 10, 2013
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Antidepressant + Placebo · For: Major Depressive Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Costa Mesa, California · 101 sites in all
- Long-term Effectiveness of the Antiobesity Medication PhenterminePivotal-lookingCompleted
Wake Forest University Health SciencesAcademic, hospital or other
NCT05176626 · 870 participants · Start Jun 30, 2022 · Primary completion Sep 30, 2026
Drug: Phentermine Hydrochloride 8 MG · For: Obesity; Obesity; Drug; Lifestyle, Healthy
Sites: Los Angeles, California; Saint Louis Park, Minnesota; Winston-Salem, North Carolina · 4 sites in all
- The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)Pivotal-lookingRecruiting
International Peace Maternity and Child Health HospitalAcademic, hospital or other
NCT06006091 · 858 participants (planned) · Start Aug 1, 2023 · Primary completion Aug 1, 2026
Drug: Letrozole · For: Letrozole; Infertility, Female
Sites: Shanghai, China
- A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00563368 · 756 participants · Start Dec 2007 · Primary completion Sep 2008
Drug: VI-0521; VI-0521 and 5 more · For: Obesity
Sites: Durham, North Carolina; Philadelphia, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxicity to various agents1,620
- drug abuse1,301
- completed suicide666
- overdose409
- death354
- cardiac arrest280
- cardio-respiratory arrest266
- drug ineffective237
- respiratory arrest216
- fatigue203
- drug dependence188
- drug interaction185
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 12 |
| 2006 | 13 |
| 2007 | 15 |
| 2008 | 16 |
| 2009 | 1 |
| 2010 | 7 |
| 2011 | 42 |
| 2012 | 36 |
| 2013 | 227 |
| 2014 | 264 |
| 2015 | 393 |
| 2016 | 258 |
| 2017 | 327 |
| 2018 | 439 |
| 2019 | 498 |
| 2020 | 507 |
| 2021 | 417 |
| 2022 | 463 |
| 2023 | 512 |
| 2024 | 673 |
| 2025 | 751 |
| 2026 | 411 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Adzenys XR-ODT (Amphetamine)
2024 spending
$1.1M
Beneficiaries
367
2,030 claims
Per beneficiary
$3,082
$16.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $490,523 |
| 2021 | $545,688 |
| 2022 | $576,313 |
| 2023 | $1,168,346 |
| 2024 | $1,131,274 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.
Faraone SV · Neurosci Biobehav Rev 2018 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.
Murrie B, Lappin J, Large M, et al. · Schizophr Bull 2020 · Meta-Analysis, Systematic Review
- Substance use and spine density: a systematic review and meta-analysis of preclinical studies.
Oliva HNP, Prudente TP, Nunes EJ, et al. · Mol Psychiatry 2024 · Systematic Review, Meta-Analysis
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
Tardelli VS, Bisaga A, Arcadepani FB, et al. · Psychopharmacology (Berl) 2020 · Meta-Analysis, Systematic Review
- Methamphetamine use and illicit opioid use during buprenorphine treatment.
Kratina-Hathaway Z, Radick AC, Leroux BG, et al. · J Subst Use Addict Treat 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F, Hutton B, Núñez-Beltrán A, et al. · PLoS One 2017 · Systematic Review, Network Meta-Analysis
Sponsor: Neos Theraps
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.